Ep. 391 - China deals, Beam lawsuit, MFN models, Nobel winners

Episode 391

0:00-30:09

Pharma partnering in China is getting earlier and broader, with Merck & Co., Novo Nordisk and Novartis striking multibillion-dollar deals for assets spanning new modalities and disease areas. On the latest BioCentury This Week podcast, BioCentury's analysts assess the trend and why co-development deals could draw scrutiny in Washington. The analysts also discuss the complexities of Beam's trade secret suit against YolTech, why the GLOBE Medicare pricing model matters more for the precedent it sets than for its savings, and the Nobel Prize for optogenetics as the first therapy based on the technology nears an FDA decision. View full story: https://www.biocentury.com/article/661028 #ChinaBiotech #DrugPricing #IntellectualProperty #DrugDevelopment #NobelPrize 0:00 Introduction 1:30 China Pharma Deal Trends 11:29 Beam vs. YolTech Lawsuit 20:01 Small GLOBE, Big Precedent 24:05 Nobel Prize & Optogenetics To submit a question to BioCentury’s editors, email the BioCentury This Week team at podcasts@biocentury.com. Reach us by sending a text

Publisher

BioCentury This Week

Published

October 6, 2026

Duration

30 min

Format

Podcast

Category

Issues · Science

Source

RSS feed

Host

BioCentury

BT

BioCentury This Week

@biocenturythisweek

#chinadeals #beamlawsuit #nobelwinners #lifesciences

The Nile